Overview

The Cancer Genetics and Genomics Program includes a group of outstanding investigators making important and major contributions to the understanding of the molecular mechanisms underlying oncogenesis, the identification of genes that contribute to and confer susceptibility to cancer, and the translation of genomic signatures into clinical practice. This is a very interactive and integrated group of investigators that form a cohesive unit focused on the common goals of identifying genes involved in oncogenesis and their role in the development of human cancer. The activities of the program are organized into two specific areas of scientific focus that include cancer genetics, with a focus on the identification of genes that define risk of onset for disease; and cancer genomics, that involve programs applying technologies, particularly DNA microarray analysis, to better understand the characteristics of tumors. These two aspects of the Program are tightly integrated and exceedingly synergistic with work flowing between each to influence the activities of the others.  Indeed, we view a major strength of the Cancer Genetics and Genomics program to be the interrelated activity – discoveries in work on oncogenic signaling pathways feeds the cancer genetics and genomics activities. Conversely, advances made in genomic applications to cancer outcomes have impacted the study of oncogenic pathways.  Indeed, this integration has led to the successful competition of a major NCI funded program in systems biology – the Integrated Cancer Biology Program – in which the focus of the program is tightly linked with activities of the Cancer Genetics and Genomics Program. Perhaps most importantly, studies in the program have led to the development of a series of genomic signatures for the prediction of lung cancer outcomes, chemotherapy sensitivity, and pathway activation tied to response to targeted therapeutics in which the science has formed the basis for translational studies in the form of multiple prospective clinical trials. The Program includes 21 members from 9 basic and clinical departments within Duke University. From 2004-2008, program members published 558 papers in peer-reviewed journals cited in PubMed. Of these publications, 10% are the result of intra-programmatic collaborations and 23.1% due to inter-programmatic collaborations.

Duke Institute for Genome Sciences & Policy

High-Impact Journal Publications

Below are recent publications in high-impact journals from Cancer Center members in this program. To see journal articles for a particular member, click on the researcher's name in the Membership section.

---

Anguiano A,Tuchman SA,Acharya C,Salter K,Gasparetto C,Zhan F,Dhodapkar M,Nevins J,Barlogie B,Shaughnessy JD Jr,Potti A. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma., , (4197-203) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Ellis MJ,Gao F,Dehdashti F,Jeffe DB,Marcom PK,Carey LA,Dickler MN,Silverman P,Fleming GF,Kommareddy A,Jamalabadi-Majidi S,Crowder R,Siegel BA. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study., , (774-80) - JAMA : the journal of the American Medical Association Abstract [More ...]

Febbo PG. Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer., , (3088-90) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology No abstract available [More ...]

Heintzman ND,Hon GC,Hawkins RD,Kheradpour P,Stark A,Harp LF,Ye Z,Lee LK,Stuart RK,Ching CW,Ching KA,Antosiewicz-Bourget JE,Liu H,Zhang X,Green RD,Lobanenkov VV,Stewart R,Thomson JA,Crawford GE,Kellis M,Ren B. Histone modifications at human enhancers reflect global cell-type-specific gene expression., . Nature Abstract [More ...]

Mendiratta P,Mostaghel E,Guinney J,Tewari AK,Porrello A,Barry WT,Nelson PS,Febbo PG. Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer., . Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Hsu DS,Acharya CR,Balakumaran BS,Riedel RF,Kim MK,Stevenson M,Tuchman S,Mukherjee S,Barry W,Dressman HK,Nevins JR,Powers S,Mu D,Potti A. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer., . Proceedings of the National Academy of Sciences of the United States of America Abstract [More ...]

Read TA,Fogarty MP,Markant SL,McLendon RE,Wei Z,Ellison DW,Febbo PG,Wechsler-Reya RJ. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma., , (135-47) - Cancer cell Abstract [More ...]

Whitehead KJ,Chan AC,Navankasattusas S,Koh W,London NR,Ling J,Mayo AH,Drakos SG,Jones CA,Zhu W,Marchuk DA,Davis GE,Li DY. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases., , (177-84) - Nature medicine Abstract [More ...]

Garman KS,Acharya CR,Edelman E,Grade M,Gaedcke J,Sud S,Barry W,Diehl AM,Provenzale D,Ginsburg GS,Ghadimi BM,Ried T,Nevins JR,Mukherjee S,Hsu D,Potti A. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities., , (19432-7) - Proceedings of the National Academy of Sciences of the United States of America Abstract [More ...]

Califf RM,Ginsburg GS. Organizational improvements to enhance modern clinical epidemiology., , (2300-2) - JAMA : the journal of the American Medical Association No abstract available [More ...]

---

Click here for these and other high-impact publications in this research program.